VILI and MSCs, page-19

Every body has obviously been hard at it doing some brilliant research. Thank you all so much for sharing.
We have come to manufacturing and appropriate reimbursement, obviously the addressable market is many hundreds times the size of aGVHD possible even thousands of times larger.
One of the major problems that MSB has for many years and is also why we were able to purchase the technology is manufacturing capabilities ,storage, transport, and preparing the end dose . This has all been due to low volume numbers of patients.
Fresh is best ! No need to freeze , defrost, and clean .
The economics of scale will be a huge price saving and substantially reduce the quantities required per person treatment.
While it is my understanding that the trial will be testing remestemcell , I think it would be wise to have a second arm testing the fresh product. For one we need every effective dose that we can manufactur, use of fresh cells could double our capacity and avoiding the need to freeze faw and prepare the final does would have a significant impact on economics and work load on what is a already over stretched medical system.
Sorry I haven't provided links to support my suggestion, it is simply my opinion derived from my understanding of the many articles that I have read over several years.
Please do your own research,
Good luck.